Program
elranatamab
Also written as “Elranatamab”, “Elranatamab (PF-06863135)” and “Elranatamab + Nirogacestat”.
Its studies are mostly in Multiple Myeloma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 137 open or running | phase 4since Sep 5, 2023 | Aug 16, 2017 | Aug 4, 2027phase 3 · NCT05317416 |
| Bristol-Myers Squibb | 11 open or running | phase 2since May 16, 2025 | May 16, 2025 | May 31, 2027phase 2 · NCT06988488 |
| Hoffmann-La Roche | 11 open or running | phase 1since Jun 22, 2023 | Jun 22, 2023 | Jul 31, 2027phase 1 · NCT05927571 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Aug 16, 2017.
- Nov 6, 2020Phase 2 study in Multiple MyelomaPfizer · NCT04649359 · 187 enrolled · United States, Australia, Belgium and more
- Mar 1, 2021Phase 1 study in RecurrencePfizer · NCT04798586 · 4 enrolled · Japan
- Jul 28, 2021Named elranatamabINNProposed as its International Nonproprietary Name in WHO's List 125
- Aug 3, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05014412 · 86 enrolled · United States, Japan, Taiwan and more
- Aug 11, 2021Phase 3 study in Multiple MyelomaPfizer · NCT05020236 · 893 planned · United States, Argentina, Australia and more
- Oct 8, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05090566 · 46 enrolled · United States, Canada
- Jan 5, 2022Phase 2 study in Neoplasms, Plasma CellPfizer · NCT05228470 · 39 enrolled · China
- Mar 18, 2022Phase 3 study in Multiple MyelomaPfizer · NCT05317416 · 854 enrolled · United States, Australia, Austria and more
- Oct 26, 2022Phase 3 study in Multiple MyelomaPfizer · NCT05623020 · 1,060 planned · United States, Argentina, Australia and more
- Jun 22, 2023Hoffmann-La Roche’s first study: phase 1 study in RecurrenceNew to Hoffmann-La RocheHoffmann-La Roche · NCT05927571 · 120 planned · Australia, Israel, South Korea
- Sep 5, 2023Phase 4 study in Multiple MyelomaPfizer · NCT06057402 · 80 planned · United States, Australia, Canada and more
- Nov 17, 2023Phase 3 study in Multiple MyelomaPfizer · NCT06152575 · 492 planned · United States, Argentina, Australia and more
- Jan 10, 2024Phase 1 study in Multiple MyelomaPfizer · NCT06215118 · 100 enrolled · United States, Australia, Canada
- May 16, 2025Bristol-Myers Squibb’s first study: phase 2 study in Multiple MyelomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT06988488 · 62 planned · United States, Canada, China and more
- Oct 13, 2026Phase 4 study in Multiple MyelomaPfizer · NCT07881835 · 75 planned
Ahead
- May 31, 2027Primary completion: phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT06988488
- Jul 31, 2027Primary completion: phase 1 study in RecurrenceHoffmann-La Roche · NCT05927571
- Aug 4, 2027Primary completion: phase 3 study in Multiple MyelomaPfizer · NCT05317416
- Nov 16, 2027Primary completion: phase 1 study in Multiple MyelomaPfizer · NCT06215118
TargetBeta
“A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07881835Multiple Myeloma | 4 | Not yet recruiting | Pfizer | Feb 16, 2029 | 75 |
| NCT06988488Multiple Myeloma · United States, Canada, China and more | 2 | Recruiting | Bristol-Myers Squibb | May 31, 2027 | 62 |
| NCT06215118Multiple Myeloma · United States, Australia, Canada | 1 | Active, not recruiting | Pfizer | Nov 16, 2027 | 100 |
| NCT06152575Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Aug 26, 2026 | 492 |
| NCT06057402Multiple Myeloma · United States, Australia, Canada and more | 4 | Recruiting | Pfizer | Feb 22, 2032 | 80 |
| NCT05927571Recurrence · Australia, Israel, South Korea | 1 | Recruiting | Hoffmann-La Roche | Jul 31, 2027 | 120 |
| NCT05623020Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Oct 18, 2030 | 1,060 |
| NCT05317416Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Pfizer | Aug 4, 2027 | 854 |
| NCT05228470Neoplasms, Plasma Cell · China | 2 | Completed | Pfizer | Aug 6, 2023 | 39 |
| NCT05090566Multiple Myeloma · United States, Canada | 2 | Terminated | Pfizer | Feb 13, 2025 | 46 |
| NCT05020236Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Pfizer | Feb 26, 2026 | 893 |
| NCT05014412Multiple Myeloma · United States, Japan, Taiwan and more | 2 | Completed | Pfizer | Jun 15, 2023 | 86 |
| NCT04798586Recurrence · Japan | 1 | Completed | Pfizer | May 27, 2022 | 4 |
| NCT04649359Multiple Myeloma · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Jun 17, 2022 | 187 |
| NCT03269136Multiple Myeloma · United States, Canada | 1 | Completed | Pfizer | Jan 19, 2024 | 101 |
How it is read
Names in the registry
- “Elranatamab”, 12 entries
- “Elranatamab (PF-06863135)”, 2 entries
- “Elranatamab + Nirogacestat”, 1 entry
- “Elranatamab + lenalidomide + dexamethasone”, 1 entry
- “PF-06863135 monotherapy IV or SC”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 15 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.